ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the recipient of a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 843,100 shares, a decline of 17.3% from the March 15th total of 1,020,000 shares. Based on an average trading volume of 476,600 shares, the short-interest ratio is presently 1.8 days. Currently, 1.1% of the company's shares are sold short.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. HC Wainwright raised their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Friday, March 14th. Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Friday, March 14th. Oppenheimer began coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an "outperform" rating and a $15.00 price target for the company. Finally, Citigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective on the stock in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $9.50.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in PRQR. Jane Street Group LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth about $30,000. Invesco Ltd. bought a new stake in ProQR Therapeutics during the fourth quarter worth about $32,000. Alpine Global Management LLC acquired a new position in ProQR Therapeutics during the fourth quarter valued at approximately $39,000. Two Sigma Securities LLC bought a new position in ProQR Therapeutics in the fourth quarter valued at approximately $40,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $54,000. Institutional investors and hedge funds own 32.65% of the company's stock.

ProQR Therapeutics Stock Performance

NASDAQ PRQR traded down $0.11 during trading on Friday, hitting $1.44. The stock had a trading volume of 139,802 shares, compared to its average volume of 594,208. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $4.62. The company's 50-day moving average price is $1.66 and its two-hundred day moving average price is $2.50. The company has a market capitalization of $150.98 million, a PE ratio of -4.48 and a beta of 0.25.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).